Decreased risk of liver cancer with thiazolidinediones therapy in patients with type 2 diabetes: Results from a meta-analysis

Hepatology

Volumn 58, Issue 2, 2013, Pages 835-836

  Wang, Feng ^a   Zhao, Shu Zhi ^b   Zhang, Ming Yue ^c   Ma, Yan Lei ^a   Zhang, Peng ^a   Qin, Huan Long ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

CANCER RISK; DIABETIC PATIENT; HUMAN; LETTER; LIVER CANCER; META ANALYSIS (TOPIC); MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; THIAZOLIDINEDIONES;

EID: 84881023478     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26259     Document Type: Letter

References (2)

1. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA.Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.Hepatology 2012;55:1462-1472.
2. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD.Metformin and reduced risk of cancer in diabetic patients.BMJ 2005;330:1304-1305.